Post TAVI pacemaker implantation does not increase mortality

Original Title: Impact of New-Onset Left Bundle Branch Block and Periprocedural Permanent Pacemaker Implantation on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. A Systematic Review and Meta-Analysis. Reference: Ander Regueiro et al. Circ Cardiovasc Interv. 2016 May;9(5).   Available data on the clinical impact of the new-onset left bundle branch block (LBBB) and<a href="https://solaci.org/en/2016/05/30/post-tavi-pacemaker-implantation-does-not-increase-mortality/" title="Read more" >...</a>

TriGuard: NeuroProtection Device during TAVI

Original Title: A Patient Level Pooled Analysis of NeuroProtection with the TriGuard Embolic DEFLECTion Device Compared to Unprotected Transcatheter Aortic Valve Replacement. Presenter: Alexandra Lansky   This work was designed to assess the safety and efficacy of the TriGuard device as a complement during transcatheter aortic valve implantation (TAVI) compared to no protection in a<a href="https://solaci.org/en/2016/05/20/triguard-neuroprotection-device-during-tavi/" title="Read more" >...</a>

PARTNER cohort B: Clinical events at 3 years follow-up in patients with

Background: Percutaneous aortic valve implantation (TAVI) is the treatment of choice for patients with severe aortic stenosis considered inoperable according to clinical outcomes at 12 months as reported in the PARTNER study, which demonstrated a reduction in mortality and an improvement in the quality of life for patients. However, the long term benefit of this<a href="https://solaci.org/en/2015/06/24/partner-cohort-b-clinical-events-at-3-years-follow-up-in-patients-with/" title="Read more" >...</a>

PARTNER 2: Edwards SAPIEN XT is even better. Results for PARTNER II, cohort B.

In the PARTNER 1 study, patients with inoperable severe aortic stenosis treated with an aortic valve prosthesis balloon-expandable Edwards-SAPIEN showed a mortality reduction compared with standard treatment. However, the Edwards SAPIEN device is associated with peri-procedural complications. The new generation of Edwards SAPIEN XT prosthesis incorporates significant improvements in the profile of the delivery system,<a href="https://solaci.org/en/2015/06/24/partner-2-edwards-sapien-xt-is-even-better-results-for-partner-ii-cohort-b/" title="Read more" >...</a>

Clinical results of TAVI in Asia

Since all the studies available in the literature were conducted in North America or Europe, the results of percutaneous aortic valve replacement in Asia are unknown. We included 253 patients with severe aortic stenosis who received TAVI at 14 sites in Asia (Edwards Sapiens: 140 patients; Medtronic Core Valve: 113 patients). The success rate was<a href="https://solaci.org/en/2015/06/24/clinical-results-of-tavi-in-asia/" title="Read more" >...</a>

The largest series of post TAVI coronary occlusion published

Original title: Predictive Factors, Management and Clinical Outcomes of Coronary obstruction Following Transcatheter Aortic Valve Implantation Insight From a Large Multicenter Registry Reference: Henrique B. Ribeiro, et; al. J Am Coll Cardiology 2013;62:1552-62 Percutaneous implantation of the aortic valve is a valid strategy in high-risk surgical patients. One of the possible complications of this procedure is the occlusion<a href="https://solaci.org/en/2013/10/29/the-largest-series-of-post-tavi-coronary-occlusion-published/" title="Read more" >...</a>

Low flow impact on outcomes following TAVI should be taken into account

Original title: Impact of Low Flow on the Outcome of High-Risk Patients Undergoing Transcatheter Aortic Valve Replacement. Reference: Florent Le Ven, et al. J Am Coll Cardiol 62;9:792-788 A study of low flow (SVi <35ml/m2) in the context of severe aortic stenosis has shown it is a predictor of worse outcomes after surgery, even though evolution with medical<a href="https://solaci.org/en/2013/08/26/low-flow-impact-on-outcomes-following-tavi-should-be-taken-into-account/" title="Read more" >...</a>

Prosthetic endocarditis after TAVI, rare and difficult to diagnose

Original title: Prosthetic valve endocarditis after transcatheter aortic valve implantation: the incidence in a single-centre cohort and reflections on clinical, echocardiographic and prognostic features. Reference: Miriam Puls et al. EuroIntervention 2013;8:1407-1418. Prosthetic valve endocarditis is a serious complication of surgical valve replacement and occurs in 0.3 to 1.2% of patients per year. It is basically divided in early<a href="https://solaci.org/en/2013/05/15/prosthetic-endocarditis-after-tavi-rare-and-difficult-to-diagnose/" title="Read more" >...</a>

The need for pacemaker post TAVI does not change the prognosis

Original title: Impact of Permanent Pacemaker Implantation on Clinical Outcome Among Patients Undergoing Transcatheter Aortic Valve Implantation. Reference: Lutz Buellesfeld et al. J Am Coll Cardiol 2012;60:493–501 Although pacemaker implantation after a percutaneous aortic valve (TAVI) implantation, constitutes a significant proportion of the complications related to the procedure, this is generally considered a benign event.  This study analyzed<a href="https://solaci.org/en/2013/03/25/the-need-for-pacemaker-post-tavi-does-not-change-the-prognosis/" title="Read more" >...</a>

TAVI, more risky in patients with peripheral vascular disease

Reference: Sinning et al. AHJ Am Heart J 2012;164:102-110 Percutaneous aortic valve replacement (TAVI) is a novel technique for the treatment of severe aortic stenosis (SAS) that has been built with great enthusiasm in clinical practice, particularly in patients with excessive surgical risk. In these patients, a high obstructive peripheral vascular disease stands, a fact<a href="https://solaci.org/en/2012/10/01/tavi-more-risky-in-patients-with-peripheral-vascular-disease/" title="Read more" >...</a>